The future of precision oncology rests largely in molecular profiling. With the development of next-generation sequencing (NGS) methods, it’s never been easier to identify multiple cancer-associated genomic changes within an individual patient’s tumor. Understanding these changes sets the stage for developing individualized treatments.
How can somatic NGS tests be analyzed and interpreted?
There are four emerging molecular profiling trends in how somatic NGS test are being analyzed and interpreted, including the following:
- Liquid biopsies
- Comprehensive genomic profiling
- Long-read sequencing
- Integrated analysis of germline and somatic variants
Interpreting data poses a particular challenge. Dan Richards, PhD, explains how your lab can perform high quality variant interpretation that is up-to-date, consistent, and professional using the QCI Interpret One clinical decision support software.
How can you effortlessly generate diagnostics reports of patient NGS data that are clinically interpretable?
Understanding the patient's genetic profile is crucial, particularly for rare cancers where biological and clinical knowledge is still lacking. As a genomics lab, you may be spending considerable time and effort generating diagnostic reports that are clinically interpretable.
Instead, your lab could benefit from fully automated analyses of patients' profiles using comprehensive software. QCI Interpret One is a clinical decision making software that does the following:
- transparently collates information about variants from various databases,
- reliably annotates variants,
- curates information manually through clinical experts to aid interpretation,
- includes suggestions on whether germline genetic testing is needed, and
- allows for customizable reports based on the information being sought.
How can you comprehensively but easily discern biological relevance of the detected variants for clinical decision making?
A thorough understanding of the data about individual variants illuminates the biological relevance and therapeutic actionability in rare cancers. Powerful software like QCI Interpret One can thus aid clinical decision making, including determining the prognosis, diagnosis, and therapeutic options available for individuals with rare cancers.